A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 7, Issue 2, 2004, Pages 117-123

  Tuǧal, Önder ^a   Yazici, Kâzim M ^a   Yaǧcioǧlu, A Elif Anil ^a   Göǧüş, Ahmet ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acetylcholine; Cognitive; Donepezil; Schizophrenia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; NICOTINIC RECEPTOR;

ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DESENSITIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG POTENCY; EVALUATION; HUMAN; INTELLIGENCE TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VERBAL BEHAVIOR; WECHSLER MEMORY SCALE; WISCONSIN CARD SORTING TEST;

ADULT; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 17544402307     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703004024     Document Type: Article

References (41)

1. Addington D, Addington J, Maticka-Tindale E (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research 6, 201-208.
2. Addington J, Addington D (1999). Neurocognitive and social functioning in schizophrenia. Schizophrenia Bulletin 25, 173-182.
3. Addington J, Addington D (2000). Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophrenia Research 44, 47-56.
4. Addington J, Addington D, Gasbarre L (2001). Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophrenia Research 48, 367-368.
5. Allen T, McEvoy JP, Keefe R, Levin E, Wilson W (2003). Galantamine improves cognition in patients with schizophrenia. Poster presented at the biennial meeting of the International Congress on Schizophrenia Research, Colorado Springs, Colorado.
6. Anil AE, Kivircik BB, Batur S, Kabakçi E, Kitiş A, Güven E, Başar K, Turgut Tİ, Arkar H (2003). The Turkish Version of the Auditory Consonant Trigram Test as a measure of working memory: a normative study. Clinical Neuropsychologist 17, 159-169.
7. Bennett JP, Enna SJ, Bylund DB, Gillin C, Wyatt RJ, Snyder SH (1979). Neurotransmitter receptors in frontalcortex in schizophrenia. Archives of General Psychiatry 36, 927-934.
8. Bilder RM (1996). Neuropsychology and neurophysiology in schizophrenia. Current Opinions in Psychiatry 9, 57-62.
9. Buchanan RW, Summerfelt A, Tek C, Gold J (2002). An open labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophrenia Research 59, 29-33.
10. Davis KL, Mohs R, Tinklenberg J, Pfefferbaum A, Hollister L, Kopell B (1978). Physostigmine: improvement of long-term memory in normal humans. Science 201, 272-274.
11. Demir B, Göǧüş A, Savaşir I (2000). Cognitive functions in depressed patients [in Turkish]. Turkish Journal of Psychiatry 11, 179-189.
12. Drachman D, Glosser G, Fleming P, Longenecker G (1982). Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 32, 944-950.
13. Ertugrul A, Ulug B (2002). The influence of neurocognitive deficits and symptoms on disability in schizophrenia. Acta Psychiatrica Scandinavica 105, 196-201.
14. Fleiss JL (1986). The Design and Analysis of Clinical Experiments (pp. 279-281). New York: John Wiley and Sons.
15. Francis PT, Palmer AM, Snape M, Wilcock GK (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery, and Psychiatry 66, 137-147.
16. Freedman R, Hall M, Adler LE, Leonard S (1995). Evidence in post mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry 38, 22-33.
17. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parella M, Davis KL (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for cognitive impairment of schizophrenia. Biological Psychiatry 51, 349-357.
18. Friedman JI, Temporini H, Davis KL (1999). Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry 45, 1-16.
19. Giacobini E (1998). Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochemistry International 32, 413-419.
20. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophrenia Bulletin 26, 119-136.
21. Goldberg TE, Gold JM (1995). Neurocognitive functioning in patients with schizophrenia. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 1245-1257). New York: Raven Press.
22. Heaton RK (1981). Wisconsin Card Sorting Manual. Odessa, Florida, Psychological Assessment Resources.
23. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA (1986). Prevalance of smoking among psychiatric outpatients. American Journal of Psychiatry 143, 993-997.
24. Hyde TM, Crook JM (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena. Journal of Chemistry and Neuroanatomy 22, 53-63.
25. Karson CN, Mrak RE, Husain MM, Griffin WS (1996). Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Molecular Chemistry and Neuropathology 29, 181-191.
26. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
27. Kostakoglu E, Batur S, Tiryaki A, Göǧüş A (1999). Reliability and validity of the Turkish version of the positive and negative syndrome scale. Turkish Journal of Psychology 14, 23-32.
28. Lohr JB, Flynn K (1992). Smoking and schizophrenia. Schizophrenia Research 8, 93-102.
29. MacEwan GW, Ehmann TS, Khanbhai I, Wrixon C (2001). Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatrica Scandinavica 104, 469-472.
30. Oksay S, Aksaray G, Kaptanoǧlu C, Bal C (2000). Validity and reliability of the Turkish version of Calgary Depression Scale in schizophrenic patients [in Turkish]. Turkish Journal of Psychiatry 11, 278-284.
31. Ratkowsky DA, Evans MA, Allredge JR (1992). In: Cross-over Experiments: Design, Analysis and Application (pp. 77-120). New York: Marcel Dekker.
32. Reitan RM, Wolfson D (1985). The Halstead-Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press.
33. Stryjer R, Bar F, Strous RD, Baruch Y, Rabey JM (2002). Donepezil management of schizophrenia with associated dementia. Journal of Clinical Psychopharmacology 22, 226-229.
34. Stryjer R, Strous RD, Bar F, Werber E, Shaked G, Buhiri Y, Kotler M, Weizman A, Rabey JM (2003). Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology 26, 12-17.
35. Tandon R (1999). Cholinergic aspects of schizophrenia. British Journal of Psychiatry 37, 7-11.
36. Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF (1992). Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacology Bulletin 28, 297-302.
37. Wechsler D (1987). Wechsler Memory Scale - Revised. New York: The Psychological Corporation.
38. Weinberger DR, Gallhofer B (1997). Cognitive function in schizophrenia. International Clinical Psychopharmacology 12, 29-36.
39. Weiss EM, Bilder RM, Fleischhacker WW (2002). The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berlin) 162, 11-17.
40. WHO (1993). WHO/MNH Battery of Cognitive Assessment Instrument Pre-pilot Battery. Geneva: World Health Organization.
41. Zahn T, Pickar D, Haier R (1994). Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research 13, 133-144.